Cell and gene therapies (CGTs) have been gaining traction within the medical community as treatment options that are expected to replace existing lifelong treatments for the management of chronic diseases. Specifically, CGTs should require fewer doses than current long-term treatments, which could offer significant benefits for both patients and strained healthcare systems. Over the past decade, a total of 14 CGTs were approved across various therapy areas in the US. According to leading data and analytics company GlobalData’s Drugs Database, of these 14 therapies that were approved by the US Food and Drug Administration (FDA), more than 70% were approved within the last five years (2019-2023).
Read the full article: Cell and Gene Therapy Landscape in the US //
Source: https://www.clinicaltrialsarena.com/analyst-comment/cell-gene-therapy-landscape-us